Tafamidis

Generic Name: Tafamidis

Brand Names: Vyndamax, Vyndaqel

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₇Cl_₂NO_₃

CAS Number: 594839-88-0

Unique Ingredient Identifier: 8FG9H9D31J

Background: Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal.

Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.

Indication: Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.

Associated Conditions: Cardiomyopathy

Associated Therapies: -

Clinical Trials

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Active, not recruiting

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions: Drug: Tafamidis

First Posted Date: 2024-05-01

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT06393465

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

Recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy

Interventions: Drug: Tafamidis

First Posted Date: 2023-10-17

Last Posted Date: 2024-04-25

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT06086353

Locations: 🇮🇳
Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India

Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

Completed

Conditions: Hereditary Transthyretin Amyloidosis (ATTRv)
Polyneuropathy

Interventions: Drug: Tafamidis

First Posted Date: 2022-09-29

Last Posted Date: 2024-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 5

Registration Number: NCT05560555

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitari de Bellvitge, Barcelona, Spain
🇪🇸
Hospital Son Llatzer, Palma de Mallorca, Spain

This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

Completed

Conditions: Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

Interventions: Drug: tafamidis

First Posted Date: 2021-12-01

Last Posted Date: 2023-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05139680

Locations: 🇺🇸
Pfizer, New York, New York, United States

The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients

Phase 4

Completed

Conditions: Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Interventions: Drug: tafamidis meglumine

First Posted Date: 2021-04-02

Last Posted Date: 2024-03-12

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04828993

Locations: 🇨🇳
Peking union hospital of Chinese academy of medical sciences, Beijing, China
🇨🇳
Tiantan Hospital Capital Medical University, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

and more 5 locations

A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Phase 4

Completed

Conditions: Transthyretin Amyloid Cardiomyopathy

Interventions: Drug: Tafamidis

First Posted Date: 2021-03-24

Last Posted Date: 2024-12-18

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT04814186

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 6 locations

A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: tafamidis
Drug: rosuvastatin

First Posted Date: 2020-02-05

Last Posted Date: 2020-09-10

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04253353

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tafamidis

First Posted Date: 2018-09-07

Last Posted Date: 2019-02-11

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT03662191

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2017-09-12

Last Posted Date: 2018-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT03280173

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2017-08-30

Last Posted Date: 2018-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT03266705

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy